The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.

ABSTRACT:

Background

Adherence to oral cancer drugs is suboptimal. The Oncology Care Model (OCM) offers oncology practices financial incentives to improve the value of cancer care. We assessed the impact of OCM on adherence to oral cancer therapy for chronic myelogenous leukemia (CML), prostate cancer, and breast cancer.

Methods

Using 2014-2019 Medicare data, we studied chemotherapy episodes for Medicare fee-for-service beneficiaries prescribed tyrosine kinase inhibitors (TKIs) for CML, antiandrogens (ie, enzalutamide, abiraterone) for prostate cancer, or hormonal therapies for breast cancer in OCM-participating and propensity-matched comparison practices. We measured adherence as the proportion of days covered and used difference-in-difference (DID) models to detect changes in adhere

SUBMITTER: Keating NL 

PROVIDER: S-EPMC9194623 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature